Form 4: Insider Buys Surrozen Shares

TCG Crossover funds, a 10% owner and director, increased their stake in Surrozen, Inc. through multiple common stock purchases.

Summary

• TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., TCG Crossover GP III, LLC, and TCG Crossover Fund III, L.P., identified as a 10% owner and director of Surrozen, Inc. (SRZN), acquired additional common stock.
• On February 11, 2026, TCG Crossover Fund II, L.P. purchased 8,882 shares at $23.575 per share, and TCG Crossover Fund III, L.P. purchased 8,881 shares at $23.575 per share.
• On February 12, 2026, TCG Crossover Fund II, L.P. purchased 547 shares at $23.8625 per share, and TCG Crossover Fund III, L.P. purchased 546 shares at $23.8625 per share.
• These transactions resulted in a total acquisition of 18,856 shares of common stock.
• Following these transactions, TCG Crossover Fund II, L.P. indirectly holds 651,114 shares, and TCG Crossover Fund III, L.P. indirectly holds 651,112 shares.
• The purchases were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, as significant insider buying by a major institutional investor and director typically indicates high confidence in the company's valuation and future prospects.

Positives

• Significant insider buying by a 10% owner and director, indicating confidence in Surrozen, Inc.'s future prospects.
• The transactions were executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy rather than a reaction to immediate news.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider buying, especially by significant shareholders like TCG Crossover, can often be interpreted by the market as a positive signal, suggesting that those with deep knowledge of the company believe the stock is undervalued or has strong future potential. This is particularly relevant in the biotechnology sector where company-specific developments often drive stock performance.

Comparison to Industry Standards

• Insider buying activity is generally viewed favorably across all industries, as it aligns management/owner interests with those of public shareholders.
• Compared to typical retail investor activity, institutional insider purchases of this magnitude ($445,028.26) are substantial and reflect a high conviction level.
• While specific comparable companies or projects are not mentioned, similar insider purchases by venture capital or crossover funds in other biotech firms (e.g., Flagship Pioneering's investments in its portfolio companies, or purchases by funds like Orbimed or RA Capital) are often seen as strong endorsements of a company's long-term prospects.

Related Party Transactions

• TCG Crossover GP II, LLC, TCG Crossover Fund II, L.P., TCG Crossover GP III, LLC, and TCG Crossover Fund III, L.P., identified as 10% owners and having director representation, acquired common stock of Surrozen, Inc. through open market purchases.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased confidence from insider buying, which may lead to upward pressure on the stock price.
• Company Management: Reinforces alignment of interests between major investors and company strategy.

Key Dates

Recommendation

The significant insider buying by a 10% owner and director, TCG Crossover, signals strong conviction in Surrozen, Inc.'s future value. Such purchases, especially when executed under a 10b5-1 plan, suggest a strategic belief in the company's long-term prospects, making it an attractive entry point for investors.

Keywords

Surrozen Inc., SRZN, Insider Buying, Form 4, TCG Crossover, Stock Purchase, Beneficial Ownership, Director, 10% Owner, Biotechnology, Investment Funds